Skip to main content
. 2020 Mar 19;12(3):821. doi: 10.3390/nu12030821

Figure 3.

Figure 3

Primary efficacy end-point in analyzed populations: change in visual analog scale (VAS) pain score during observation. The score evaluation shows a statistically significantly pain intensity reduction at all the observations except in Migratens® Group at T3 (6 months and 3 months after treatment interruption according study protocol, p = 0.6).